Recorded Presentation from the 2016 NCCN Oncology Case Manager and Medical Director Program™ - New and Emerging Therapies in Colorectal Cancer
The 2016 NCCN Case Manager and Medical Director Program Live Webinar Series will consist of six webinars on the topics of colorectal cancer, prostate cancer, distress management, CML, ovarian cancer, and multiple myeloma. This educational series is designed to help case managers and medical directors manage patients with cancer based on evidence and according to the recommendations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
This program is designed to meet the educational needs of case managers, nurses in other roles (i.e., quality management and utilization review), medical directors at managed care organizations, reinsurers, TPAs, and case management and disease management companies who interact with, counsel, and refer patients with cancer to appropriate sources of care and/or make coverage decisions. Programs may also be of interest to nurses, nurse navigators/care coordinators, and physicians who work directly with patients in clinical settings as well as clinical pharmacists in managed care organizations and other settings.
Following this activity, participants should be able to:
- Evaluate new and emerging treatment options for patients with mCRC
- Explain how results of molecular testing can affect treatment decisions for patients with mCRC
- List factors that should be considered when helping patients with mCRC make informed decisions regarding their care
Alan P. Venook, MD
UCSF Helen Diller Family Comprehensive Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below have disclosed the following relevant financial relationships:
Alan P. Venook, MD
Bayer HealthCare: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support
The activity planning staff listed below has no relevant financial relationships to disclose:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
The NCCN clinical information staff listed below, who have reviewed content, has no relevant financial relationships to disclose:
Deborah Freedman-Cass, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
National Comprehensive Cancer Network designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.90 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.00 CE contact hours. Activity Code: I00023966; Approval #: 160004425
- 1.00 AMA PRA Category 1 Credit™
- 0.90 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation